Citations

Showing 10 of 108104 citations.

Rapid conjugation of nanoparticles, proteins and siRNAs to microbubbles by strain-promoted click chemistry for ultrasound imaging and drug delivery
Liu, Xifeng , Xie, Feng , Chen, Shigao , Lu, Lichun , Gong, Ping , Miller, A. Lee , Gong, Ping , Song, Pengfei , Miller, Alan Lee

Mayo Clinic

Polymer Chemistry | December 26, 2018 | Volume: 10 | Issue: 6 | Pages: 705-717

10.1039/c8py01721b | PMID 36187167 Get It

Strain-promoted alkyne–azide cycloaddition (SPAAC) click chemistry was applied for the rapid conjugation of nanoparticles, proteins, and siRNA-micelles to ultrasound microbubbles.
Alcohol Craving Predicts Relapse After Residential Addiction Treatment
Stohs, Matthew E., Schneekloth, Terry D. , Geske, Jennifer R. , Biernacka, Joanna M. , Karpyak, Victor M. , Geske, Jennifer

Mayo Clinic

Alcohol and Alcoholism | December 26, 2018 | Volume: 54 | Issue: 2 | Pages: 167-172

10.1093/alcalc/agy093 | PMID 30796778 Get It

Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing
Kumar, Shaji , Buadi, Francis K. , Rajkumar, S. Vincent

Mayo Clinic

Blood | December 26, 2018 | Volume: 133 | Issue: 7 | Pages: 652-659

10.1182/blood-2018-08-825349 | PMID 30587528 Get It

Abstract The treatment landscape for multiple myeloma has dramatically changed over the past decade with the introduction of several new classes of drugs, which are very effective at controlling the disease for prolonged periods of time, especially when used in multidrug combinations. Prior to the advent of these new agents, peripheral blood autologous stem cell transplantation (ASCT) was the mainstay of therapy for patients who were eligible to undergo the procedure, with deep and durable responses in the majority of patients. Despite the introduction of more effective therapies, ASCT continues to play an important role in overall management of younger patients, where it has been integrated with the other therapeutic approaches to provide maximum benefit. Recent phase 3 trials have once again confirmed the survival benefit associated with ASCT in myeloma. Retrospective studies have also demonstrated the feasibility of using ASCT at the time of first relapse rather than as a component of the initial treatment. Significant geographical variations exist in the use of ASCT, especially between the United States and Europe in terms of its use as part of upfront therapy. Much of these differences are driven by the availability of drugs and drug combinations for initial therapy of myeloma as well as maintenance approaches post-ASCT. It is amply clear from these trials that ASCT will continue to play an important role in management of myeloma and is likely to be used as a platform for enhancing the efficacy of other treatment modalities that are currently in development.
Automated Abdominal Segmentation of CT Scans for Body Composition Analysis Using Deep Learning
Weston, Alexander D. , Korfiatis, Panagiotis , Kline, Timothy L. , Philbrick, Kenneth A. , Kostandy, Petro, Sakinis, Tomas , Sugimoto, Motokazu , Takahashi, Naoki , Takahashi, Naoki , Erickson, Bradley J. , Weston, Alexander D

Mayo Clinic

Radiology | December 26, 2018 | Volume: 290 | Issue: 3 | Pages: 669-679

10.1148/radiol.2018181432 | PMID 30526356 Get It

Comparing Real-Time Self-Tracking and Device-Recorded Exercise Data in Subjects with Type 1 Diabetes
Groat, Danielle , Kwon, Hyo, Thompson, Bithika , Grando, Maria Adela, Cook, Curtiss B. , Grando, Adela

Mayo Clinic

Applied Clinical Informatics | December 26, 2018 | Volume: 09 | Issue: 04 | Pages: 919-926

10.1055/s-0038-1676458 | PMID 30586673 Get It

Background Insulin therapy, medical nutrition therapy, and physical activity are required for the treatment of type 1 diabetes (T1D). There is a lack of studies in real-life environments that characterize patient-reported data from logs, activity trackers, and medical devices (e.g., glucose sensors) in the context of exercise. Objective The objective of this study was to compare data from continuous glucose monitor (CGM), wristband heart rate monitor (WHRM), and self-tracking with a smartphone application (app), iDECIDE, with regards to exercise behaviors and rate of change in glucose levels. Methods Participants with T1D on insulin pump therapy tracked exercise for 1 month with the smartphone app while WHRM and CGM recorded data in real time. Exercise behaviors tracked with the app were compared against WHRM. The rate of change in glucose levels, as recorded by CGM, resulting from exercise was compared between exercise events documented with the app and recorded by the WHRM. Results Twelve participants generated 277 exercise events. Tracking with the app aligned well with WHRM with respect to frequency, 3.0 (2.1) and 2.5 (1.8) days per week, respectively (p = 0.60). Duration had very high agreement, the mean duration from the app was 65.6 (55.2) and 64.8 (54.9) minutes from WHRM (p = 0.45). Intensity had a low concordance between the data sources (Cohen's kappa = 0.2). The mean rate of change of glucose during exercise was –0.27 mg/(dL*min) and was not significantly different between data sources or intensity (p = 0.21). Conclusion We collated and analyzed data from three heterogeneous sources from free-living participants. Patients' perceived intensity of exercise can serve as a surrogate for exercise tracked by a WHRM when considering the glycemic impact of exercise on self-care regimens.
Geographical Differences in Intracranial Meningioma Management: Examining 65,973 Patients across the United States
Anzalone, C. Lane , Glasgow, Amy E. , Habermann, Elizabeth B. , Grossard, Brandon R., Carlson, Matthew L. , Glasgow, Amy E. , Anzalone, Charles Lane, Glasgow, Amy, Habermann, Elizabeth , Gompel, Jamie J. Van , Glasgow, Amy E

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | December 26, 2018 | Volume: 80 | Issue: 06 | Pages: 547-554

10.1055/s-0038-1676376 | PMID 31754594 Get It

Background Age, tumor size and location, overall health, and patient preference are primary considerations driving treatment decision-making for intracranial meningiomas. However, even for the same individual patient, treatment recommendations may vary between centers and providers. Objective To study associations between geography, disease presentation, and management of intracranial meningioma in the United States. Methods The population-based Surveillance, Epidemiology, and End Results(SEER) data were queried between 2004 and 2014 for cases of intracranial meningioma. Results A total of 65,808 patients with intracranial meningioma were identified. Univariate analyses demonstrated strong associations between geographic location, age, and size of tumor at presentation. The mean age for all registries was 64.2 years, with a range from 62.0 (Utah registry) to 66.6 (Detroit registry). The greatest proportion of small tumors (<1 cm) were identified in the Utah registry (13.9% of tumors), while the greatest proportion of large tumors (> 4cm) were noted in the Hawaii registry (30.7% of tumors). Multivariable analysis demonstrated that the impact of geography on treatment selection was just as important as other established variables. For example, the distribution in tumor size between New Mexico and Greater California registries is nearly identical; however, the odds ratio for surgery was 1.5 times greater for the New Mexico population. Conclusion These data suggest that disease presentation and treatment are significantly influenced by regional referral patterns, provider or institutional treatment preferences, and regional availability of subspecialty expertise. Understanding such biases is important for patients, referring physicians, and treatment providers in an effort to provide balanced counseling and treatment.
Body Composition Technology: Implications for the ICU
Mundi, Manpreet S. , Patel, Jayshil J. , Martindale, Robert G.

Mayo Clinic

Nutrition in Clinical Practice | December 26, 2018 | Volume: 34 | Issue: 1 | Pages: 48-58

10.1002/ncp.10230 | PMID 30586471 Get It

AbstractMalnutrition continues to be highly prevalent in hospitalized and critically ill patients and is associated with significant morbidity and mortality. Additionally, survivors of critical illness have an increased risk for sarcopenia, which leads to weakness and physical debilitation that can persist for years. Nutrition risk assessment tools have been developed and validated in critically ill patients but have limitations. Variables such as body weight, body mass index, weight change, or percentage of food intake can be difficult to obtain in critically ill patients and may be misleading given changes in body composition, such as an increase in body water. Assessment of body composition through new techniques provides a unique opportunity to counter some of these limitations and develop improved methods of nutrition risk assessment based on objective data. The present manuscript provides a review of the most commonly available clinical technology for assessment of body composition (bioimpedance, computed tomography, and ultrasound), including data from trials in critically ill patients highlighting the benefits and weaknesses of each modality.
Development of Quality Measures in Cirrhosis by the Practice Metrics Committee of the American Association for the Study of Liver Diseases
Kanwal, Fasiha , Tapper, Elliot B. , Ho, Chanda , Asrani, Sumeet K. , Ovchinsky, Nadia , Poterucha, John J., Flores, Avegail , Ankoma‐Sey, Victor, Luxon, Bruce A. , Volk, Michael L. , Poterucha, John, Asrani, Sumeet K

Mayo Clinic

Hepatology | December 26, 2018 | Volume: 69 | Issue: 4 | Pages: 1787-1797

10.1002/hep.30489 | PMID 30586188 Get It

Health care delivery is increasingly evaluated according to quality measures, yet such measures are underdeveloped for cirrhosis. The Practice Metrics Committee of the American Association for the Study of Liver Diseases was charged with developing explicit process‐based and outcome‐based measures for adults with cirrhosis. We identified candidate measures from comprehensive reviews of the literature and input from expert clinicians and patient focus groups. We conducted an 11‐member expert clinician panel and used a modified Delphi method to systematically identify a set of quality measures in cirrhosis. Among 119 candidate measures, 46 were identified as important measures to define the quality of cirrhosis care, including 26 process measures, 7 clinical outcome measures, and 13 patient‐reported outcome measures. The final process measures captured care processes for ascites (n = 5), varices/bleeding (n = 7), hepatic encephalopathy (n = 4), hepatocellular cancer (HCC) screening (n = 1), liver transplantation evaluation (n = 2), and other care (n = 7). Clinical outcome measures included survival, variceal bleeding and rebleeding, early‐stage HCC, liver‐related hospitalization, and rehospitalization within 7 and 30 days. Patient‐reported outcome measures covered physical symptoms, physical function, mental health, general function, cognition, social life, and satisfaction with care. The final list of patient‐reported outcomes was validated in 79 patients with cirrhosis from nine institutions in the United States. Conclusion: We developed an explicit set of evidence‐based quality measures for adult patients with cirrhosis. These measures are a tool for providers and institutions to evaluate their care quality, drive quality improvement, and deliver high‐value cirrhosis care. The quality measures are intended to be applicable in any clinical care setting in which care for patients with cirrhosis is provided.
Letter by Vilanilam et al Regarding Article, “Collateral Clock Is More Important Than Time Clock for Tissue Fate: A Natural History Study of Acute Ischemic Strokes”
Vilanilam, George K. , Badi, Mohammed K. , Gopal, Neethu , Vilanilam, George , Badi, Mohammed, Badi, Mohammed

Mayo Clinic

Stroke | December 26, 2018 | Volume: 49 | Issue: 12 | Pages: No page available

10.1161/strokeaha.118.023379 | PMID 30571443 Get It